ENTITY
Lonza Group

Lonza Group (LONN SE)

17
Analysis
Health Care • Switzerland
Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. The company works with healthcare customers to develop, manufacture and commercialize medical treatments and technologies to treat patients against a range of diseases. Founded in the Swiss Alps, Lonza now operates across Europe, North America, South America, Asia and Oceania.
more
bullish•Wuxi Biologics
•15 Feb 2017 01:41

An Early Look at WuXi Biologics

WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing.  The document...

Share
bullish•Samsung Biologics
•05 Feb 2017 16:08

Revisiting Samsung BioLogics at This Interesting Time

I don't really intend to make any investment recommendation on BioLogics at this point. I have to admit that I'm still feeling the current price is...

Logo
371 Views
Share
bearish•Samsung Biologics
•15 Nov 2016 03:49

Samsung Biologics IPO: Another Way for the Company's Relative Valuation

We used price/sales ratio for relative valuation of Samsung Biologics Co., Ltd (207940 KS) , a growing company that has yet to show an operating...

bullish•Samsung Biologics
•11 Nov 2016 06:05

Recap of Samsung BioLogics' First Trading Day - Foreign Institutions Net Purchased 1M Shares

Samsung BioLogics closed at ₩144,000 with 6.67% gain on its first trading day. It started with a relatively weak sentiment at the opening price of...

Logo
327 Views
Share
bullish•Samsung Biologics
•10 Nov 2016 06:20

Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction

As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....

Logo
405 Views
Share
x